8 terminated, 1 withdrawn. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 6, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Rain Oncology Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL) - Advanced or Metastatic Breast Cancer | Phase 2 | Terminated | Institut Curie | 1 | 2023-10-12 | 2023-12-21 |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Milademetan, Atezolizumab - Advanced Solid Tumor, CDKN2A | Phase 1 / Phase 2 | Withdrawn | Rain Oncology Inc | 2023-05-19 | 2023-10-19 | |
| A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects Placebo, Moxifloxacin (positive control), Milademetan - Cardiac Repolarization | Phase 1 | Terminated | Rain Oncology Inc | 6 | 2023-04-17 | 2023-08-08 |
| Tarlox and Sotorasib in Patients With KRAS G12C Mutations Sotorasib and Tarloxotinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Medical University of South Carolina | 5 | 2022-03-07 | 2025-12-16 |
| Milademetan in Advanced/Metastatic Solid Tumors RAIN-32 - Solid Tumors, Head and Neck Carcinoma | Phase 2 | Terminated | Rain Oncology Inc | 40 | 2021-11-01 | 2024-10-17 |
| Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma RAIN-32, Trabectedin - Dedifferentiated Liposarcoma | Phase 3 | Terminated | Rain Oncology Inc | 175 | 2021-07-14 | 2025-01-14 |
| Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions tarloxotinib bromide - NSCLC, Stage IV, NSCLC Stage IIIB | Phase 2 | Terminated | Rain Oncology Inc | 41 | 2019-03-13 | 2023-06-28 |
| Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin TH-4000 (Tarloxotinib) - Metastatic Head-and-neck Squamous-cell Carcinoma | Phase 2 | Terminated | Rain Oncology Inc | 30 | 2015-08-01 | 2023-01-12 |
| Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients TH-4000 (Tarloxotinib) - Non-small Cell Lung Cancer, NSCLC | Phase 2 | Terminated | Rain Oncology Inc | 21 | 2015-06-01 | 2023-01-12 |
Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Squamous Cell (2) · Hypoxia (2) · Melanoma (2) · Sarcoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Adenocarcinoma of Lung (1) · Adrenocortical Carcinoma (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Liposarcoma (1) · Mesothelioma (1)
milademetan (5) · Fulvestrant (1) · Moxifloxacin (1) · Patient Reported Outcome Measures (1) · Quality of Life (1) · Trabectedin (1) · atezolizumab (1) · sotorasib (1)
United States (6) · Australia (3) · Canada (2) · France (2) · Hong Kong (2) · Austria (1) · Belgium (1) · Georgia (1) · Germany (1) · Ireland (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1)
Stephen Liu (2) · Stephen V Liu, MD (1)